Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies
August 23 2018 - 7:00AM
Business Wire
--Achieves #1 ranking for both 3-year EPS and
revenue growth--
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the
Company”) today announced that the Company has been named to the
Fortune 100 List of Fastest-Growing Companies, ranking 16th
overall, including achieving the #1 positions for EPS 3-year growth
of 392% and revenue 3-year growth of 109%.
“We are extremely proud of how our team has executed on our
overall growth strategy. We continue to see excellent opportunities
ahead for our business,” stated Scott Tarriff, Chief Executive
Officer of Eagle Pharmaceuticals.
Fortune's list ranks public companies, with market
capitalization of $250 million or more, based on revenue
growth rate, EPS growth rate and three-year annualized total return
for the period ended June 30, 2018.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on
developing and commercializing injectable products that address the
shortcomings, as identified by physicians, pharmacists and other
stakeholders, of existing commercially successful injectable
products. Eagle’s strategy is to utilize the FDA's 505(b)(2)
regulatory pathway. Additional information is available on the
company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended and other securities laws. Forward-looking
statements are statements that are not historical facts. Words such
as “will,” “continue,” “may,” “believe,” “intends,”
“anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and
similar expressions are intended to identify forward-looking
statements. These statements include statements regarding future
events including, but not limited to: Eagle’s ability to defend
against third party attempts to design around or invalidate its
patents; successful compliance with FDA and other governmental
regulations applicable to product approval, manufacturing
facilities, products and/or businesses; the FDA’s ability to
approve any drug applications referencing BENDEKA prior to December
2022; the ability of generic TREANDA products to enter the market
prior to 2022; Eagle’s market protection for BENDEKA; the
commercial success of Eagle’s commercial portfolio, including
BENDEKA; successful compliance with FDA and other governmental
regulations; the ability of Eagle to deliver sustained shareholder
value over time; and other factors that are discussed in Eagle’s
Annual Report on Form 10-K for the year ended December 31, 2017,
and its other filings with the U.S. Securities and Exchange
Commission. All of such statements are subject to certain risks and
uncertainties, many of which are difficult to predict and generally
beyond Eagle’s control, that could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. Such risks include, but
are not limited to whether Eagle’s management and/or board of
directors will be effective in managing Eagle’s business and future
growth, as well as the other risks described in Eagle’s filings
with the U.S. Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof, and we do not
undertake any obligation to revise and disseminate forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of or non-occurrence of any
events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180823005126/en/
Investor Relations for Eagle Pharmaceuticals, Inc.:Lisa
M. Wilson, 212-452-2793lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024